Guggenheim Initiates Coverage On Entrada Therapeutics with Buy Rating, Announces Price Target of $20
Entrada Therapeutics Inc -0.29% Post
Entrada Therapeutics Inc TRDA | 13.99 13.99 | -0.29% 0.00% Post |
Guggenheim analyst Debjit Chattopadhyay initiates coverage on Entrada Therapeutics (NASDAQ:
TRDA) with a Buy rating and announces Price Target of $20.